Core Viewpoint - The legal opinion letter confirms that the 2024 annual general meeting of Shanghai Ruiang Gene Technology Co., Ltd. was convened and conducted in accordance with relevant laws and regulations, ensuring the legality and validity of the meeting and its resolutions [2][14]. Group 1: Meeting Procedures - The annual general meeting was convened by the company's board of directors, with the notice published 20 days prior to the meeting date [4][5]. - The meeting utilized a combination of on-site and online voting methods, with specific time slots designated for each voting method [5][14]. Group 2: Attendance and Voting - A total of 33 shareholders and their proxies attended the meeting, representing 17,949,661 shares, which is 32.5256% of the total voting shares [6]. - The meeting included 3 shareholders present on-site, representing 10,804,197 shares (19.5777% of total voting shares), while 30 shareholders participated via online voting [6][7]. Group 3: Resolutions Passed - The meeting approved several resolutions, including: - The 2024 Board of Directors' Work Report, with 99.3652% approval from attending shareholders [8]. - The 2024 Supervisory Board's Work Report, also receiving 99.3652% approval [9]. - The 2024 Financial Settlement Report, with the same level of approval [10]. - The 2025 Financial Budget Report, approved by 99.3391% of attending shareholders [10]. - The 2024 Profit Distribution Plan, receiving 99.3652% approval [10]. - The 2024 Annual Report and its summary, with 99.3652% approval [11]. - The 2025 Director Remuneration Plan, approved by 99.2735% of attending shareholders [12]. - The 2025 Supervisor Remuneration Plan, also receiving 99.2735% approval [12]. - The proposal for a comprehensive credit limit application to banks for 2025, approved by 99.2980% of attending shareholders [13]. Group 4: Legal Compliance - The legal opinion confirms that the meeting's convening, attendance, voting procedures, and resolutions comply with the Company Law, Securities Law, and other relevant regulations [14].
睿昂基因: 上海市锦天城律师事务所关于上海睿昂基因科技股份有限公司2024年年度股东大会的法律意见书